智通财经APP讯，绿叶制药(02186)发布公告，集团自主研发的创新制剂利斯的明透皮贴剂(2次╱W)已获得日本厚生劳动省的新药上市批准，用于抑制轻至中度阿尔茨海默病痴呆症状的进展。利斯的明透皮贴剂(2次╱W)在日本的商品名为Rivaluen® LA Patch 25.92 mg/51.84 mg，是当前首款在日本市场获批上市的利斯的明缓释透皮贴剂产品。
Rivaluen® LA Patch 25.92 mg/51.84 mg基于集团在欧洲的透皮释药技术平台开发，通过创新的给药途径经皮肤每周给药两次，而活性成分为利斯的明。该产品的获批基于在日本完成的一项治疗阿尔茨海默病相关痴呆症III期临床试验的积极结果。该项临床研究已达到主要疗效终点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.